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ABSTRACT
Objective: To evaluate gender differences in the
prognostic value of renal function for mortality in ST-
segment elevation myocardial infarction (STEMI)
patients undergoing primary percutaneous coronary
intervention (PPCI).
Design: Prospective single-center cohort.
Setting: Single tertiary referral center in Amsterdam,
The Netherlands. Patients consecutive STEMI patients
undergoing PPCI (1412 men and 558 women).
Main outcome measure: The authors calculated
adjusted HRs for 3-year all-cause mortality according
to the presence of a reduced renal function (estimated
glomerular ﬁltration rate <60 ml/min) using Cox
proportional hazards models. In order to investigate
a possible gender difference in the prognostic value of
a reduced renal function, a comparison was made
between the HRs of male and female patients and an
interaction term was added to the model and tested for
signiﬁcance. Adjustments were made for age, body
mass index, history of diabetes or hypertension,
systolic blood pressure and heart rate, anterior
myocardial infarction and time to treatment.
Results: In male patients, a reduced renal function
was associated with increased 3-year mortality
(adjusted HR 6.31, 95% CI 3.74 to 10.63, p<0.001). A
reduced renal function was associated with a twofold
increase in the mortality hazard in female patients
(adjusted HR 2.22, 95% CI 1.25 to 3.94, p¼0.006).
Conclusions: In this large single-centre registry of
STEMI patients undergoing PPCI, renal dysfunction as
assessed by estimated glomerular ﬁltration rate had
prognostic signiﬁcance for mortality in both male and
female patients.
INTRODUCTION
Even in mild forms, renal dysfunction as
assessed by the estimated glomerular ﬁltra-
tion rate (eGFR) is a major risk factor for
adverse cardiovascular outcomes after
myocardial infarction.
1 Renal dysfunction is
more prevalent among women presenting
with ST-elevation myocardial infarction
(STEMI), although female patients
presenting with STEMI are generally older
and have more comorbidities when
compared with male patients.
12A recently
performed single-centre study in Sweden
showed a clear gender difference in the
prevalence and prognostic impact of renal
insufﬁciency in STEMI patients undergoing
primary percutaneous coronary intervention
(PPCI).
3 In this cohort, 67% of female
patients had renal insufﬁciency, deﬁned as an
eGFR <60 ml/min, compared with 26% of
the male patients. Moreover, a prognostic
impact of renal insufﬁciency on 1-year
mortality was only observed in female
patients, even after adjustments for baseline
differences between both genders. This
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ARTICLE SUMMARY
Article focus
- To evaluate gender differences in the prognostic
value of renal function in ST-segment elevation
myocardial infarction patients undergoing
primary percutaneous coronary intervention.
Key message
- Renal dysfunction has prognostic signiﬁcance for
mortality in both male and female patients.
Strengths and limitations of this study
- Renal function was routinely measured at
admission in a large tertiary referral center.
- Single-center cohort and information on the
cause of death was not available.
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Open Access Researchcounterintuitive ﬁnding deserves conﬁrmation. In the
current manuscript, the main objective was to evaluate
gender differences in the relation between renal func-
tion and outcomes in STEMI patients undergoing PPCI
in a large single centre in the Netherlands.
METHODS
Source population and procedures
We used data from consecutive STEMI patients who
underwent PPCI in our centre between 1 January 2005
and 1 January 2009. The PPCI and adjunctive pharmaco-
logical treatment were performed according to ACC/AHA
and ESC guidelines. In general, patients were eligible for
PPCI if they presented with ischaemic chest pain, onset of
symptoms #12 h prior to presentation and at least 1 mm
of ST-segment elevation in two contiguous leads on the 12-
lead electrocardiogram. Patients received aspirin
(500 mg), clopidogrel (300e600 mg) and unfractioned
heparin (5000 IU). Glycoprotein IIb/IIIa inhibitors were
used at the discretion of the operator. If a coronary stent
was implanted, clopidogrel was prescribed for at least
1 month to patients with a bare metal stent and for at least
6 months following a dug-eluting stent.
eGFR and biomarkers
Blood samples prior to PPCI were obtained as part of
routine clinical care. Blood samples were drawn imme-
diately after insertion of the arterial sheath prior to PPCI
for assessment of cardiac troponin T (cTnT), C reactive
protein, glucose, N-terminal pro-brain natriuretic peptide
(NT-pro-BNP) and plasma creatinine. Blood samples were
centrifuged without undue delay and analysed. Both
cTnT and NT-pro-BNP were measured using a Hitachi
modular E-170 analyzer (Roche Diagnostics GmbH,
Mannheim, Germany). C reactive protein was measured
with an immunoturbidimetric assay, and glucose and
plasma creatinine were measured with an enzymatic assay
on a Hitachi modular P-800 (Roche Diagnostics GmbH).
The eGFR was calculated according to the Cockcroft and
Gault formula.
4 For our current study, an eGFR of 60 ml/
min was deﬁned as a reduced renal function.
5
Data collection
Our local catheterisation laboratory database was
consulted for information about the patients’ demo-
graphics, procedural and angiographic characteristics
that had been prospectively collected and entered by
interventional cardiologists and specialised nurses.
Study population
For the current analysis, we included all STEMI patients
who underwent PPCI between 1 January 2005 and 1
January 2009 and had eGFR measured prior to percu-
taneous coronary intervention. Patients in whom we
were not able to calculate an eGFR were excluded. Only
the ﬁrst PPCI was included in case of a patient with
multiple PPCIs within the time window (n¼66). We
excluded STEMI patients undergoing rescue percuta-
neous coronary intervention after failed thrombolysis
(n¼28). Ten patients were removed because they had
symptoms lasting longer than 12 h.
Outcomes
The outcome for our current analysis was all-cause
mortality. Information on vital status obtained from the
institutional database was synchronised with the Dutch
national population registry.
Statistical analysis
Normally distributed continuous variables were
compared with the Student t test and skewed-distributed
variables with the Wilcoxon rank-sum test. Categorical
variables were compared with the c
2 test. Follow-up was
right censored at 3 years or at last known follow-up,
whichever came ﬁrst. The prognostic value of eGFR was
assessed by investigating the relation between mortality
and eGFR in two sets of Cox proportional hazards anal-
yses: univariable analyses and multivariable analysis with
adjustments for age or established predictors of mortality
(complete case analysis). The following established
prognostic factors derived from the Thrombolysis In
Myocardial Infarction (TIMI) score were included in the
model: age, body weight, history of diabetes, hyperten-
sion, systolic blood pressure and heart rate, anterior
myocardial infarction and time to treatment (symptom
onset to ﬁrst balloon inﬂation).
6 7 The interaction
between gender and renal function was assessed by
entering an interaction term in the Cox proportional
hazards model. In an exploratory analysis, we added NT-
pro-BNP, glucose and shock to the established predictors
in the multivariable Cox proportional hazards model.
Both biomarkers were added as categorical variables
according to previously described cut-offs.
8 Cumulative
event rates were estimated with the KaplaneMeier
method and compared with the log-rank test. We plotted
KaplaneMeier curves for the following categories: eGFR
<45 ml/min, eGFR 45e59 ml/min and eGFR $60 ml/
min.
9 A p value of <0.05 was deemed signiﬁcant.
RESULTS
We included 1970 patients with a measured eGFR in our
current study. Of these patients, 1412 (71.7%) were men
and 558 (28.3%) were women. The baseline character-
istics of the study patients are presented in table 1.
Women were older and had a higher prevalence of risk
factors. Generally, the biomarkers were more deviant in
women.
Regarding renal function in male patients, 91.2% had
an eGFR $60, 4.9% of 45e69 and 3.9% of <45 ml/min.
In female patients, these percentages were, respectively,
75.3%, 14.9% and 9.9% (p<0.001 for the comparison
between male and female patients).
Outcomes
No patients were lost to follow-up. At 3-year follow-up,
240 of the 1970 patients died (cumulative mortality
13.7%). Although there was a signiﬁcant difference in
mortality according to gender (11.7% in men vs 18.8%
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Prognostic value of eGFR and gender in STEMIin women, HR 0.58, 95% CI 0.45 to 0.76, p<0.001), this
difference was not signiﬁcant after adjustment for age
(HR 0.89, 95% CI 0.68 to 1.17, p¼0.42). A decreasing
renal function was associated with increasing 3-year
mortality in both male and female patients (ﬁgure 1).
As shown by the Cox proportional hazards models in
table 2, an eGFR of <60 ml/min was associated with
higher unadjusted 30-day and long-term mortality in
both genders (p<0.001 for all).
An eGFR <60 ml/min remained a strong independent
predictor for short- and long-term mortality irrespective
of patient gender after adjustments for age or estab-
lished predictors for mortality (p<0.01 for all). Impor-
tantly, the interaction term between gender and renal
function was signiﬁcant because overall higher mortality
hazards were observed in male patients compared with
female patients.
Furthermore, renal dysfunction remained associated
with increased mortality (HR 5.82, 95% CI 2.91 to 11.66,
p<0.001) in male patients after addition of the addi-
tional biomarkers NT-proBNP and glucose. In women,
a weakened HR was observed for renal dysfunction, most
likely due to lack of power (HR 1.22, 95% CI 0.56 to 2.65,
p¼0.61). After addition of shock to the established risk
factors, the HRs were, respectively, 7.05 (95% CI 3.84 to
12.96, p<0.001) in male and 1.48 (95% CI 0.78 to 2.81,
p¼0.23) in female patients.
DISCUSSION
In accordance with multiple observational and rando-
mised trials, we observed an independent graded effect
of renal insufﬁciency on the risk of all-cause mortal-
ity.
10e12 This relationship was strong for both genders,
although we noted a signiﬁcant quantitative but not
qualitative interaction between the genders. After
multivariable risk adjustments, male patients with an
eGFR below 60 ml/min were at the highest risk for
mortality.
Table 1 Baseline characteristics of the study patients according to gender and renal function
Characteristics
Men (n[1412) Women (n[558)
p Value*
eGFR
<60 ml/min
(n[124)
eGFR
‡60 ml/min
(n[1288) p Value
eGFR
<60 ml/min
(n[138)
eGFR
‡60 ml/min
(n[420) p Value
Demographics
Age (year) 756 (9) 596 (12) <0.001 786 (9) 626 (13) <0.001 0.005
Body mass index 256 (3.7) 276 (3.8) <0.001 256 (3.9) 286 (10) <0.001 0.19
Risk factors
Current smoking 33 (27%) 560 (44%) <0.001 25 (18%) 179 (41%) <0.001 0.098
Hypertension 48 (39%) 360 (28%) 0.012 62 (45%) 144 (34%) 0.025 0.31
Hypercholesterolaemia 19 (15%) 264 (21%) 0.17 21 (15%) 99 (24%) 0.04 0.98
Diabetes mellitus 20 (16%) 126 (10%) 0.027 29 (21%) 62 (15%) 0.085 0.31
Clinical history
Myocardial infarction 38 (36%) 163 (13%) <0.001 28 (22.0%) 36 (9.3%) <0.001 0.025
Percutaneous coronary
intervention
25 (21%) 126 (10%) <0.001 8 (6.1%) 31 (7.6%) 0.55 <0.001
Coronary artery
bypass grafting
4 (3.5%) 22 (1.8%) 0.19 5 (3.8%) 8 (2.0%) 0.24 0.91
Laboratory assessments
Troponin T (mg/l) 0.04
(0.09e0.59)
0.04
(0.04e0.20)
<0.001 0.15
(0.04e0.74)
0.05
(0.04e0.26)
0.001 0.15
Glucose (mmol/l) 8.9
(7.0e11.7)
7.9
(6.7e9.5)
<0.001 9.1
(7.3e11.2)
8.2
(6.9e10.1)
0.003 0.72
NTproBNP (ng/l) 980
(340e3728)
102
(50e341)
<0.001 1012
(307e5027)
180
(99e627)
<0.001 0.81
eGFR (ml/min) 456 (12) 1166 (37) e 46 (10) 1056 (42) ee
Procedural characteristics
Systolic blood pressure,
mm Hg
1236 (32) 1286 (27) 0.11 1356 (35) 1366 (30) 0.59 0.006
Heart rate, bpm 806 (21) 776 (17) 0.21 796 (20) 796 (19) 0.79 0.92
Shock 14 (11.4%) 37 (2.9%) <0.001 10 (7.3%) 15 (3.6%) 0.074 0.26
Anterior myocardial
infarction
58 (47%) 502 (39%) 0.17 49 (36%) 172 (41%) 0.26 0.06
Time to
treatment (min)
223
(153e321)
179
(125e269)
0.013 201
(132e338)
188
(141e276)
0.49 0.07
Data are presented as absolute n (%), mean6 (SD) or median (IQR).
*p Value for differences in characteristics between male and female patients with eGFR <60 ml/min.
CRP, C reactive protein; eGFR, estimated glomerular ﬁltration rate; NTproBNP, N-terminal pro-brain natriuretic peptide.
Damman P, Kikkert WJ, Woudstra P, et al. BMJ Open 2012;2:e000322. doi:10.1136/bmjopen-2011-000322 3
Prognostic value of eGFR and gender in STEMIQuantitative gender difference in prognostic value eGFR
In multivariable adjustments, a signiﬁcant quantitative
interaction was observed between gender and renal
function with regard to prognostic value for mortality.
An explanation for this interaction may be found in
gender differences in the prevalence of factors mecha-
nistically linking renal dysfunction with mortality. Such
factors include age, hypertension, dyslipidemia, diabetes
mellitus and peripheral vascular disease.
13 Male patients
with renal dysfunction were younger but had a higher
incidence of previous myocardial infarction (MI) or
revascularisation compared with female patients.
However, adjustment for these factors did not materially
alter the HRs of the shown multivariable models. Other
factors associated with both renal dysfunction and
mortality did not signiﬁcantly differ between men and
women with renal dysfunction.
A second explanation for the gender difference in
prognostic value of renal dysfunction could be that there
were differences in concomitant therapy. Therapeutic
nihilism has been suggested as a possible mechanism for
worse outcomes with renal dysfunction.
1 However, we
did not observe differences in PPCI incidence, stent use
or glycoprotein IIb/IIIa inhibitor use. Furthermore, we
previously described a comparable quality of care in
male and female patients.
14
Renal dysfunction is associated with anaemia, endo-
thelial dysfunction, increased homocysteine levels,
procoagulant coagulopathy, systemic inﬂammation,
hyperparathyroidism with associated disorder in
calciumephosphate homeostasis and increased risk of
contrast-induced nephropathy, all of which potentially
deteriorate atherosclerosis or outcomes.
1 13 15 Some of
these factors were not measured in our database; there-
fore, we cannot rule out important differences between
the sexes in these factors. Therefore, residual unob-
served confounding may have contributed to the differ-
ences between male and female patients.
Finally, the quantitative difference might be a spurious
ﬁnding as indicated by the broad CIs.
Previous studies
The observation that eGFR is an independent risk factor
for both male and female patients is in contrast to the
recently published Swedish single-centre study. In this
study, no prognostic value of eGFR was observed in male
patients.
3 In 247 STEMI patients, the unadjusted ORs for
each 10 ml/min increment in eGFR for 1-year mortality
in female and male patients with renal dysfunction were
0.37 and 1.05, respectively. After multivariable adjust-
ment, the HR remained unaltered and statistically
signiﬁcant in women. In contrast, the adjusted OR for
male patients with renal dysfunction was 1.10. It is
unlikely that this difference has arisen from differences
in baseline descriptors and procedural characteristics
between the Swedish cohort and our cohort, as these are
small. One notable exception might be the higher
percentage of female patients with renal dysfunction in
the Swedish study population. In our estimation, in view
of the lack of a biological rationale for the difference, the
most important explanation for the difference between
the two studies could be the number of patients. We
observed a signiﬁcant difference in mortality between
patients with eGFR >60 ml/min and patients with
45e59 ml/min, while the cumulative mortality curves for
these groups were almost superimposable in the Swedish
cohort probably due to lack of power. Other possible
explanations might be that the male patients with an
Figure 1 Long-term mortality according to gender and renal
function. The upper panel shows the KaplaneMeier curves in
male patients and the lower panel in female patients. p Value
by the log-rank test for overall comparison.
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Prognostic value of eGFR and gender in STEMIeGFR >60 ml/min generally had a more favourable
baseline risk proﬁle compared with the female patients
with an eGFR >60 ml/min.
Finally, in the Swedish study, the eGFR was estimated
with the modiﬁcation of diet in renal disease equation.
We estimated the eGFR with the Cockcroft and Gault
formula. However, if we assume that all patients are non-
black and calculate the eGFR with the modiﬁcation of
diet in renal disease equation, results are consistent.
In concordance with the Swedish study, a second study
showed a stronger association between renal dysfunction
and outcomes in female patients, although renal
dysfunction had prognostic signiﬁcance in both sexes.
2
However, this study was performed in patients under-
going coronary angiography regardless of indication.
This hampers direct comparison because mortality is
higher in STEMI patients than in stable coronary artery
disease patients.
Limitations
Several limitations of the current analysis have to be
addressed. First, this study was performed using data
from a large single-centre registry. This could be
a potential source for selection bias. However, the data
concerns a large heterogeneous group of STEMI
patients treated by PPCI in a high-volume tertiary
referral centre with surgical backup. Second, informa-
tion on vital status was obtained from the Dutch national
population registry, wherein information on the cause of
death is not available.
Conclusions
In our large single-centre registry of STEMI patients
undergoing PPCI, renal dysfunction as assessed by eGFR
had prognostic signiﬁcance for mortality in both male
and female patients. This emphasises the role of renal
function as both a prognostic marker as well as a poten-
tial therapeutic target in the treatment of atherosclerotic
disease.
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Table 2 Prognostic value of reduced admission eGFR for 30-day and long-term mortality according to gender
Variable
Mortality
Male HR (95% CI) p Value
Female HR
(95% CI) p Value
P for
interaction
Thirty-day mortality
Univariable
eGFR <60 ml/min 12.6 (8.10 to 19.7) <0.001 6.27 (3.53 to 11.1) <0.001 <0.001
Multivariable
eGFR <60 ml/min 13.59 (5.67 to 32.61) <0.001 6.42 (1.89 to 21.9) 0.003
Age 1.00 (0.97 to 1.04) 0.90 1.04 (1.01 to 1.07) <0.01
Multivariable*
eGFR <60 ml/min 11.58 (5.39 to 24.91) <0.001 3.41 (1.38 to 8.44) 0.008 0.005
Multivariable*
eGFR 45e60 ml/min 7.29 (2.84 to 18.72) <0.001 2.39 (0.86 to 6.61) 0.095
eGFR <45 ml/min 16.11 (7.17 to 36.21) <0.001 7.82 (2.64 to
23.17)
<0.001
Long-term mortality
Univariable
eGFR <60 ml/min 9.39 (6.73 to 13.10) <0.001 4.74 (3.15 to 7.13) <0.001 <0.001
Multivariable
eGFR <60 ml/min 5.09 (3.38 to 7.69) <0.001 2.54 (1.56 to 4.13) <0.001
Age 1.04 (1.02 to 1.06) <0.001 1.05 (1.02 to 1.07) <0.001
Multivariable*
eGFR <60 ml/min 6.31 (3.74 to 10.63) <0.001 2.22 (1.25 to 3.94) 0.006 0.03
Multivariable*
eGFR 45e60 ml/min 3.58 (1.79 to 7.14) <0.001 1.65 (0.86 to 3.15) 0.131
eGFR <45 ml/min 5.73 (2.68 to 12.27) <0.001 4.15 (2.04 to 8.43) <0.001
For all Cox models. The reference category for the eGFR variable is eGFR $60 ml/min.
*Adjusted for age, body mass index, history of diabetes or hypertension systolic blood pressure and pulse, anterior myocardial infarction and
time to treatment.
eGFR, estimated glomerular ﬁltration rate.
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